Has signed at least 50 contracts with drug manufacturers to provide "additional rebates" under California's budget rescue package. Those include about eight to 10 contract amendments from firms who had rebate contracts directly with the California Medicaid agency rather than HCFA plus roughly 40 other contracts. At least four companies -- Merck, Lilly, Upjohn and Pfizer -- initially informed Medi-Cal that they would not provide the added rebates ("The Pink Sheet" Oct. 5, p. 3). Medi-Cal subsequently has met with all firms that declined. The state does not consider anyone out of the program yet. Eventually, products from firms that do not meet minimum rebate levels will be covered by Medi-Cal only on a prior-authorization basis.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth